Stem Cell Therapy and Administration Routes After Stroke.

Area of Science:

• Regenerative Medicine
• Neuroscience
• Stem Cell Biology

Background:

• Cell-based therapy has shown safety and efficacy in preclinical stroke models.
• Initial clinical studies confirm the safety of cell-based therapies in stroke patients.
• Significant questions persist regarding the optimal parameters for clinical translation.

Purpose of the Study:

• To review the current state of cell-based therapy for stroke.
• To identify key areas requiring further investigation for clinical optimization.
• To highlight the need for research into therapeutic windows, dosage, cell types, delivery routes, and mechanisms of action.

Main Methods:

• Review of experimental stroke models utilizing various cell delivery routes (intracerebral, intraventricular, subarachnoid, intra-arterial, intraperitoneal, intravenous, intranasal).
• Analysis of safety and efficacy data from preclinical and early clinical studies.
• Identification of knowledge gaps in understanding mechanisms of action and immune modulation.

Main Results:

• Cell-based therapies are safe in stroke patients and effective in animal models.
• Multiple delivery routes have been explored preclinically.
• Optimal clinical parameters (therapeutic window, dosage, cell source, route) remain undetermined.

Conclusions:

• Further experimental research is essential to determine the optimal clinical use of stem cell therapy for stroke.
• Investigating safety, efficacy, and mechanisms of action is crucial for refining treatment strategies.
• Translating preclinical findings into effective clinical protocols requires addressing specific optimization questions.